References
- Albarello L, Pecciarini L, Doglioni C (2011). HER2 testing in gastric cancer. Adv Anat Pathol, 18, 53-9. https://doi.org/10.1097/PAP.0b013e3182026d72
- Bauknecht T, Kohler M, Janz I, Pfleiderer A (1989). The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer: EGF receptors and factors in gynecological carcinomas. J Cancer Res Clin Oncol, 115, 193-9. https://doi.org/10.1007/BF00397923
- Gehan EA, Walker MD (1997). Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr, 46,189-95.
- Gulati S, Jakola AS, Johannesen TB, Solheim O (2012). Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg, 78, 518-26. https://doi.org/10.1016/j.wneu.2011.12.008
- Gulati S, Jakola AS, Nerland US, Weber C, Solheim O (2011). The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg, 76, 572-79. https://doi.org/10.1016/j.wneu.2011.06.014
- Haapasalo H, Hyytinen E, Sallinen P, et al (1996). c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer, 73, 620-3. https://doi.org/10.1038/bjc.1996.107
- Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN (1993). Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol, 16, 93-104. https://doi.org/10.1007/BF01324695
- Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr (2002). HER2/neu expression in malignant lung tumors. Semin Oncol, 29, 51-8.
- Haynik DM, Roma AA, Prayson RA (2007). HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol, 15, 56-8. https://doi.org/10.1097/01.pai.0000213133.09160.da
- Jakola AS, Myrmel KS, Kloster R, et al (2012). Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA, 308, 1881-8. https://doi.org/10.1001/jama.2012.12807
- Koka V, Potti A, Forseen SE, et al (2003). Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol, 26, 332-5.
- Lacroix M, Abi-Said D, Fourney DR, et al (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg, 95, 190-8. https://doi.org/10.3171/jns.2001.95.2.0190
- Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
- Mineo JF, Bordron A, Baroncini M, et al (2007). Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol, 85, 281-7. https://doi.org/10.1007/s11060-007-9424-1
- Mineo JF, Quintin-Roue I, Lucas B, Buburusan V, Besson G (2002). Glioblastomas: clinical study and search for prognostic factors. Neurochirurgie, 48, 500-9.
- Neal DE, Marsh C, Bennett MK, et al (1985). Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet, 1, 366-8.
- Ozawa S, Ueda M, Ando N, Shimizu N, Abe O (1989). Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer, 63, 2169-73. https://doi.org/10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W
- Pfeiffer D, Stellwag B, Pfeiffer A, et al (1989). Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol, 33, 146-50. https://doi.org/10.1016/0090-8258(89)90540-4
- Pigott TJ, Robson DK, Palmer J, Ward LM (1993). Expression of epidermal growth factor receptor in human glioblastoma multiforme. Br J Neurosurg, 7, 261-5. https://doi.org/10.3109/02688699309023808
- Potti A, Forseen SE, Koka VK, et al (2004). Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest, 22, 537-44. https://doi.org/10.1081/CNV-200026523
- Rainov NG, Dobberstein KU, Bahn H, et al (2007). Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol, 35, 13-28.
- Reszec J, Bernaczyk PS, Milewski R, Chyczewski L, Mariak Z (2011). C-erbB-2 protein expression in astrocytic tumors of the brain. Med Sci Monit, 17, 216-20.
- Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1, 1398-402.
- Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
- Stummer W, Reulen HJ, Meinel T, et al (2008). ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 62, 564-76. https://doi.org/10.1227/01.neu.0000317304.31579.17
- Torp SH, Gulati S, Johannessen E, Dalen A (2007). Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res, 26, 353-9.
- Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP (2011). Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg, 66, 10-17. https://doi.org/10.1179/ACB.66.1.2062508
- Yaziji H, Goldstein LC, Barry TS, et al (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 291, 1972-77. https://doi.org/10.1001/jama.291.16.1972
Cited by
- Lack of Sunlight Exposure Influence on Primary Glioblastoma Survival vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4165
- Preoperative Grading of Astrocytic Supratentorial Brain Tumors with Diffusion-Weighted Magnetic Resonance Imaging and Apparent Diffusion Coefficient vol.13, pp.3, 2016, https://doi.org/10.5812/iranjradiol.30426
- Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis vol.140, pp.12, 2017, https://doi.org/10.1002/ijc.30690